{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:49:48Z","timestamp":1790092188368,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe a series of patients who developed retinal vein occlusion (RVO) while undergoing treatment with tyrosine kinase inhibitors (TKIs) for systemic malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was performed to identify patients at an academic medical centre from 2014 to 2024 who developed an RVO while on TKI therapy. Data collected included demographics, cancer diagnosis, TKI agent and treatment duration, ocular history, and treatment outcomes. Ophthalmic imaging obtained at the time of presentation was reviewed when available to confirm the diagnosis of an RVO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven patients (12 eyes) were identified with an RVO during TKI therapy. The mean age at presentation was 75.9\u2009\u00b1\u20099.8 years, and 8 patients (72.7%) were male. TKIs included imatinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), axitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), ibrutinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), and regorafenib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). RVO developed after a mean duration of 2.8\u2009\u00b1\u20092.0 years on TKI therapy (range:\u00a00.8\u20136.5 years). Of the 12 RVOs, 8 were central retinal vein occlusions (CRVOs) and 4 were branch retinal vein occlusions (BRVOs). The mean Naranjo Adverse Drug Reaction Probability Score was 5.2, suggesting a probable link between TKI use and RVO. One patient developed bilateral RVO after continuing regorafenib therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This series highlights a possible association between TKI therapy and RVO, underscoring the need for awareness in patients with vascular risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04240-7","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:16:47Z","timestamp":1770376607000},"page":"697-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-9504","authenticated-orcid":false,"given":"Nitesh","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandni","family":"Duphare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2043-3413","authenticated-orcid":false,"given":"Mir Yusuf","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5769-0717","authenticated-orcid":false,"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"4240_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","volume":"13","author":"L Huang","year":"2020","unstructured":"Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020). J Hematol Oncol. 2020;13:143.","journal-title":"J Hematol Oncol"},{"key":"4240_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8:262.","journal-title":"Signal Transduct Target Ther"},{"key":"4240_CR3","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.htct.2024.11.113","volume":"46","author":"Kaya","year":"2024","unstructured":"Kaya. E\u0130. OPTIMIZATION OF TKI SELECTION IN CML: BALANCING EFFICACY, SAFETY, AND PATIENT PREFERENCES. Hematol Transfus Cell Ther. 2024;46:S17\u20138.","journal-title":"Hematol Transfus Cell Ther"},{"key":"4240_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11899-015-0254-5","volume":"10","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Abaza Y, Jabbour E. Selecting the Best Frontline Treatment in Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2015;10:145\u201357.","journal-title":"Curr Hematol Malig Rep"},{"key":"4240_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/eye.2017.222","volume":"32","author":"MT Bhatti","year":"2018","unstructured":"Bhatti MT, Salama AKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye. 2018;32:287\u2013301.","journal-title":"Eye"},{"key":"4240_CR6","doi-asserted-by":"crossref","unstructured":"Chen Y, Du Y, Qiu L. Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review. Front Pharmacol [Internet] 2023 [cited 2024 Mar 17];14. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2023.1188218\/full.","DOI":"10.3389\/fphar.2023.1188218"},{"key":"4240_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/09273948.2022.2042318","volume":"31","author":"R Pyare","year":"2023","unstructured":"Pyare R, Ganvir A, Goyal S, Rao C, Dutta Majumder P. Bilateral Central Retinal Vein Occlusion Associated with Axitinib Therapy: A Case Report. Ocul Immunol Inflamm. 2023;31:635\u20137.","journal-title":"Ocul Immunol Inflamm"},{"key":"4240_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-016-0536-7","volume":"18","author":"G Schvartsman","year":"2016","unstructured":"Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep. 2016;18:49.","journal-title":"Curr Oncol Rep"},{"key":"4240_CR9","doi-asserted-by":"publisher","first-page":"35181","DOI":"10.18632\/oncotarget.9285","volume":"7","author":"ZY Li","year":"2016","unstructured":"Li ZY, Fan XX, Wang YJ, et al. Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib. Oncotarget. 2016;7:35181\u20137.","journal-title":"Oncotarget"},{"key":"4240_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/ICB.0b013e3182160965","volume":"6","author":"S Szczepanik","year":"2012","unstructured":"Szczepanik S, K\u0119cik D. Bilateral central retinal vein occlusion in a patient with disseminated metastatic renal cell carcinoma treated with sorafenib. Retin Cases Brief Rep. 2012;6:148\u201350.","journal-title":"Retin Cases Brief Rep"},{"key":"4240_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101657","volume":"27","author":"W Foulsham","year":"2022","unstructured":"Foulsham W, Edghill BZ, Julia Canestraro OD, et al. Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition. Am J Ophthalmol Case Rep. 2022;27:101657.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4240_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1362108","volume":"11","author":"M Luo","year":"2024","unstructured":"Luo M, Sun L, Dai R, Chen Y, Wu C. Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review. Front Med. 2024;11:1362108.","journal-title":"Front Med"},{"key":"4240_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/724780","volume":"2014","author":"P Kolar","year":"2014","unstructured":"Kolar P. Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data. J Ophthalmol. 2014;2014:724780.","journal-title":"J Ophthalmol"},{"key":"4240_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00417-019-04337-8","volume":"257","author":"AL Kunkler","year":"2019","unstructured":"Kunkler AL, Binkley EM, Mantopoulos D, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol. 2019;257:1771\u201381.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4240_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharm Ther. 1981;30:239\u201345.","journal-title":"Clin Pharm Ther"},{"key":"4240_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-017-3386-6","volume":"80","author":"B Liu","year":"2017","unstructured":"Liu B, Ding F, Zhang D, Wei G. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis. Cancer Chemother Pharm. 2017;80:487\u201395.","journal-title":"Cancer Chemother Pharm"},{"key":"4240_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.critrevonc.2012.12.006","volume":"87","author":"G Sonpavde","year":"2013","unstructured":"Sonpavde G, Je Y, Schutz F, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol\/Hematol. 2013;87:80\u20139.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"4240_CR18","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","volume":"23","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012;23:1672\u20139.","journal-title":"Ann Oncol"},{"key":"4240_CR19","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1002\/ijc.27979","volume":"132","author":"W-X Qi","year":"2013","unstructured":"Qi W-X, Min D-L, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis. Int J Cancer. 2013;132:2967\u201374.","journal-title":"Int J Cancer"},{"key":"4240_CR20","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.18632\/oncotarget.24599","volume":"10","author":"Y Bai","year":"2018","unstructured":"Bai Y, Li J-Y, Li J, et al. Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review. Oncotarget. 2018;10:4205\u201312.","journal-title":"Oncotarget"},{"key":"4240_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","volume":"41","author":"MD Wu","year":"2021","unstructured":"Wu MD, Moslehi JJ, Lindner JR. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. Arteriosclerosis, Thrombosis Vasc Biol. 2021;41:3\u201310.","journal-title":"Arteriosclerosis, Thrombosis Vasc Biol"},{"key":"4240_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1188\/16.ONF.235-243","volume":"43","author":"ME Davis","year":"2016","unstructured":"Davis ME. Ocular Toxicity of Tyrosine Kinase Inhibitors. Oncol Nurs Forum. 2016;43:235\u201343.","journal-title":"Oncol Nurs Forum"},{"key":"4240_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/archopht.126.5.692","volume":"126","author":"PRA O\u2019Mahoney","year":"2008","unstructured":"O\u2019Mahoney PRA, Wong DT, Ray JG. Retinal Vein Occlusion and Traditional Risk Factors for Atherosclerosis. Arch Ophthalmol. 2008;126:692\u20139.","journal-title":"Arch Ophthalmol"},{"key":"4240_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.survophthal.2010.11.006","volume":"56","author":"JP Ehlers","year":"2011","unstructured":"Ehlers JP, Fekrat S. Retinal Vein Occlusion: Beyond the Acute Event. Surv Ophthalmol. 2011;56:281\u201399.","journal-title":"Surv Ophthalmol"},{"key":"4240_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.neo.7900263","volume":"4","author":"GJ Caine","year":"2002","unstructured":"Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate. Neoplasia. 2002;4:465\u201373.","journal-title":"Neoplasia"},{"key":"4240_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, et al. The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313\u20139.e1.","journal-title":"Ophthalmology"},{"key":"4240_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11037-4","volume":"23","author":"W-JA Lee","year":"2023","unstructured":"Lee W-JA, Chung W-P, Shao S-C, Lai EC-C, Chen Y-C, Ho C-H. Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors \u2013 a population-based cohort study. BMC Cancer. 2023;23:545.","journal-title":"BMC Cancer"},{"key":"4240_CR28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/aos.13860","volume":"96","author":"AP Toft-Petersen","year":"2018","unstructured":"Toft-Petersen AP, Muttuvelu DV, Heegaard S, Torp-Pedersen C. Correlation between retinal vein occlusion and cancer \u2013 a nationwide Danish cohort study. Acta Ophthalmol. 2018;96:800\u20133.","journal-title":"Acta Ophthalmol"},{"key":"4240_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.109207","volume":"244","author":"P Ortega-Toledo","year":"2024","unstructured":"Ortega-Toledo P, Rodr\u00edguez-Gaspar M\u00c1, Barrios-Padilla IC, et al. Retinal vascular events and relationship to CANCER development. Thrombosis Res. 2024;244:109207.","journal-title":"Thrombosis Res"},{"key":"4240_CR30","first-page":"Doc04","volume":"9","author":"VG Madanagopalan","year":"2019","unstructured":"Madanagopalan VG, Paneer Selvam V, Sarath Sivan NV, Govindaraju NV. Central retinal vein occlusion in a patient with breast carcinoma. GMS Ophthalmol Cases. 2019;9:Doc04.","journal-title":"GMS Ophthalmol Cases"},{"key":"4240_CR31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0002-9394(03)00716-5","volume":"136","author":"SD Adrean","year":"2003","unstructured":"Adrean SD, Schwab IR. Central retinal vein occlusion and renal cell carcinoma. Am J Ophthalmol. 2003;136:1185\u20136.","journal-title":"Am J Ophthalmol"},{"key":"4240_CR32","doi-asserted-by":"publisher","first-page":"bcr2015212463","DOI":"10.1136\/bcr-2015-212463","volume":"2015","author":"V Castro-Navarro","year":"2015","unstructured":"Castro-Navarro V, Odaibo SG, Ghodasra DH, Besirli CG. Bilateral BRVO in a patient with recurrent prostate cancer. BMJ Case Rep. 2015;2015:bcr2015212463.","journal-title":"BMJ Case Rep"},{"key":"4240_CR33","first-page":"108","volume":"85","author":"F Ronchetto","year":"1994","unstructured":"Ronchetto F. Occlusion of a branch of the central retinal vein as a manifestation of hypercoagulability in a patient with lung cancer. A possible paraneoplastic event. Recent Prog Med. 1994;85:108\u201312.","journal-title":"Recent Prog Med"},{"key":"4240_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.oftal.2012.06.007","volume":"88","author":"VM Asensio-S\u00e1nchez","year":"2013","unstructured":"Asensio-S\u00e1nchez VM, Hernaez-Ortega MC, Castresana-Jauregui I. Central retinal vein occlusion as the first symptom of ovarian cancer. Arch Soc Esp Oftalmol. 2013;88:482\u20134.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"4240_CR35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40119-022-00285-3","volume":"11","author":"M Imura","year":"2022","unstructured":"Imura M, Katada J, Shiga T. Epidemiological Study Regarding the Incidence of Venous Thromboembolism in Patients After Cancer Remission. Cardiol Ther. 2022;11:611\u201323.","journal-title":"Cardiol Ther"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04240-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:38:44Z","timestamp":1774352324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04240-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4240"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04240-7","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NM, CD, TDG, MYA, RS: None\n                      SKS:\n                      Grants from Regeneron, Eyevensys, Eyepoint, and Gilead, and consulting fees from Adverum, Novartis, Zeiss, and Bausch and Lomb.\n                      MO:\n                      Consulting or advisory roles for Eisai, Exelixis, Pfizer, Aveo, Merck, Seattle Genetics, and Bristol Myers Squibb; served on speakers bureaus for Bristol Myers Squibb; received institutional research funding from Bristol Myers Squibb, Pfizer, Merck, Astra-Zeneca, HiberCell, Arcus.\n                      DS:\n                      Consulting fees from Bayer, Deciphera, and institutional research support from Deciphera, Novartis\n                      SS\n                      : Consulting fees from 4DMT, Alimera, Abbvie, Apellis, Astellas, Bausch and Lomb, Clearside, Eyepoint, Harrow, Genetech\/Roche, Kodiak, Merck, Regeneron, RegenXBio, Ripple, Volk, and Zeiss with contracted research support from Acelyrin, Gilead, Genetech\/Roche, Santen, IONIS, Kodiak","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}